Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06919354 · ClinicalTrials.gov registry record · Phase 1
A Study of GNTI-122 in Adults Recently Diagnosed With T1D
A Phase 1 study of Type 1 Diabetes Mellitus and Type 1 Diabetes (T1D), sponsored by GentiBio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 10
- Study locations
NCT06919354 is a Phase 1 study of Type 1 Diabetes Mellitus and Type 1 Diabetes (T1D) that is actively recruiting participants, run by GentiBio. The registered enrollment target is 16 participants, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (89% lower). The trial reports 10 study locations across 5 states.
The verdict
NCT06919354, a Phase 1 study of Type 1 Diabetes Mellitus and Type 1 Diabetes (T1D), is actively recruiting participants, sponsored by GentiBio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a 78-week single arm, multi-center, Phase 1 study to evaluate the safety, tolerability, cellular kinetics, and biomarker changes in C-peptide over time of GNTI-122, an investigational cell therapy manufactured from a participant's own blood cells in adult participants with recently diagnosed T1D. After assessment of eligibility, participants who qualify for the study will be enrolled sequentially in 1 of 3 cohorts. Cohort 1 participants (n=3) receive a low dose of GNTI-122 . Cohort 2 participants (n=3) receive a high dose of GNTI-122. Cohort 3 participants (n=10) receive a high dose of GNTI-122 in combination with rapamycin. Participants are followed for 78 weeks after the administration of GNTI-122 during which safety and efficacy assessments are made, including vital signs, ECG, physical exam, clinical labs, and monitoring of adverse events and concomitant medications. Disease markers (e.g., MMTT-stimulated C-peptide, HbA1c) and pharmacodynamic activity (e.g., lymphocyte subsets and phenotypes, effector T cell responses to islet antigens ex vivo, T1D autoantibodies) will be monitored serially throughout the study. The study will include sentinel dosing and a Safety Review Committee to ensure participant safety. Visit https://www.polarisstudy.com to learn more!
Conditions Studied
Interventions
- BIOLOGICAL GNTI-122
Study Locations (10)
California
- City of Hope Medical Center - Duarte
- University of California - San Diego - San Diego
- University of California - San Francisco - San Francisco
Florida
- University of Florida - Gainesville - Gainesville
- University of Miami, Diabetes Research Institute - Miami
New York
- Icahn School of Medicine at Mount Sinai - New York
- Columbia University - New York
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
- Duke University - Durham
Massachusetts
- Joslin Diabetes Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-09-03 |
| Est. Completion | 2028-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06919354
The ClinicalTrials.gov registry entry for NCT06919354 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (89% lower). The listed sponsor is GentiBio, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which GNTI-122 is the first listed.
NCT06919354 reports 10 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT06919354 about?
NCT06919354 is a clinical study titled "A Study of GNTI-122 in Adults Recently Diagnosed With T1D". This is a 78-week single arm, multi-center, Phase 1 study to evaluate the safety, tolerability, cellular kinetics, and biomarker changes in C-peptide over time of GNTI-122, an investigational cell therapy manufactured from a participant's own blood cells in adult participants with recently diagnosed...
What is the current status of trial NCT06919354?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2025-09-03. Estimated completion is 2028-02.
What conditions does trial NCT06919354 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus, Type 1 Diabetes (T1D).
What interventions are being tested in trial NCT06919354?
The interventions under investigation include: GNTI-122 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06919354?
This trial is sponsored by GentiBio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06919354 being conducted?
This trial has 10 study locations across California, Florida, Massachusetts, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes
RECRUITING · Phase 1
-
Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
RECRUITING · Phase 1
-
An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes
ACTIVE NOT RECRUITING · Phase 1
-
A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.